ArticleAnnals of biomedical engineering2025
In Vivo Investigation of Osteogenesis and Angiogenesis of Modified Polycaprolactone-Hydroxyapatite-Zinc Oxide Electrospun Nanofibers Loaded with Metformin.
Article in Annals of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Engineering polycaprolactone nanowires for pharmacologic efficacy.Expert opinion on drug delivery · 2025Article
- Electrospinning for Mimicking Bioelectric Microenvironment in Tissue Regeneration.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Critical bone defects pose significant challenges to effective treatment. However, drug loading within scaffold structures has emerged as an advanced strategy for successful bone tissue regeneration. PURPOSE: This study investigates the effects of nano-zinc oxide (nZnO) and metformin (MET) on angiogenesis and osteogenesis in electrospun scaffolds under both in vitro and in vivo conditions.
methodsElectrospun scaffolds, composed of poly(ε-caprolactone), nano-hydroxyapatite, and nZnO, were ultrasonicated to modify pore sizes and enhance bone regeneration. Subsequently, gelatin nanoparticles containing metformin (MET/GNPs) were covalently bonded to the scaffolds. MET/GNP-loaded scaffolds were co-cultured with human umbilical vein endothelial cells and rat bone marrow mesenchymal stem cells. In vitro assays, including MTT, ALP, and alizarin red staining, were performed to assess cytotoxicity, differentiation, and mineralization, respectively. Angiogenesis and osteogenesis were further evaluated in vivo using a rat calvarial defect model through CT imaging, hematoxylin and eosin staining, Masson's trichrome staining, and immunohistochemistry (IHC).
resultsScanning electron microscopy revealed nano-scale dimensions of the fibers and nanoparticles, while dynamic light scattering confirmed nanoparticle properties. The loading content and loading efficiency of MET/GNPs were calculated as 56.4% and 12.5%, respectively. Results demonstrated significantly enhanced cell viability in MET/GNP-loaded scaffolds, along with increased ALP activity and mineralization capacity. Histological and IHC analyses confirmed successful stimulation of angiogenesis and osteogenesis in vivo.
conclusionThese scaffolds show significant potential for promoting osteogenesis and angiogenesis in bone tissue engineering.
Indexed as
Identifiers
40455276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.